












MME mutation in dominant
spinocerebellar ataxia with neuropathy
(SCA43)
ABSTRACT
Objective: To identify the causative gene mutation in a 5-generation Belgian family with domi-
nantly inherited spinocerebellar ataxia and polyneuropathy, in which known genetic etiologies
had been excluded.
Methods: We collected DNA samples of 28 family members, including 7 living affected individu-
als, whose clinical records were reviewed by a neurologist experienced in ataxia. We combined
linkage data of 21 family members with whole exome sequencing in 2 affected individuals to iden-
tify shared heterozygous variants mapping to potentially linked regions. Variants were screened
for rarity and for predicted damaging effect. A candidate mutation was confirmed by Sanger
sequencing and tested for cosegregation with the disease.
Results: Affected individuals presented with late-onset sensorimotor axonal polyneuropathy; all
but one also had cerebellar ataxia. We identified a variant in the MME gene, p.C143Y, that
was absent from control databases, cosegregated with the phenotype, and was predicted to have
a strong damaging effect on the encoded protein by all algorithms we used.
Conclusions: MME encodes neprilysin (NEP), a zinc-dependent metalloprotease expressed in
most tissues, including the central and peripheral nervous systems. The mutated cysteine 143
forms a disulfide bridge, which is 100% conserved in NEP and in similar enzymes. The recent
identification of recessive MME mutations in 10 unrelated individuals from Japan with axonal
polyneuropathy further supports the causality of the mutation, despite the dominant mode of
inheritance and the presence of cerebellar involvement in our study family. Functional studies
are needed to identify the mechanisms underlying these differences. Neurol Genet2016;2:e94; doi:
10.1212/NXG.0000000000000094
GLOSSARY
AD 5 Alzheimer disease; BGI 5 Beijing Genomics Institute; CMT2 5 Charcot–Marie–Tooth type 2; ECE 5 endothelin-
converting enzyme; EVS 5 exome variant server; NEP 5 neprilysin; PNS 5 peripheral nervous system; SNP 5 single
nucleotide polymorphism; SCA 5 spinocerebellar ataxia; WES 5 whole exome sequencing.
Autosomal dominant spinocerebellar ataxias (SCAs) are progressive disabling diseases character-
ized by dysfunction and neuronal loss in the cerebellum, the spinocerebellar tracts, or the sen-
sory tracts (posterior columns) of the spinal cord.1 There are many genetic subtypes of SCAs,
numbered from SCA1 to SCA42.
The most common SCAs are due to repeat expansions in the respective genes, resulting in
expanded polyglutamine (polyQ) tracts in the encoded proteins. Some SCAs are associated with
noncoding repeat expansion, and the remaining ones are due to point mutations or insertions/
deletions. Mutated genes encode proteins whose functions are relevant for the cerebellar system,
including calcium homeostasis, intracellular signaling, cytoskeleton, mitochondria, neuropepti-
des, and membrane ion channels.1
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Many SCA subtypes are characterized by
pathology affecting other structures in addition
to the cerebellum, with associated weakness,
pyramidal signs, sensory loss, cranial nerve
involvement, other movement disorders, intel-
lectual disability, dementia, epilepsy, optic atro-
phy, and, in the case of SCA7, retinal macular
degeneration. Peripheral neuropathy commonly
occurs in SCAs, most frequently of mixed type
with axonal and demyelinating characteristics,
but with differences among genetic subtypes.2
We investigated a 5-generation Belgian
family with dominantly inherited late-onset
cerebellar ataxia and axonal peripheral neurop-
athy. We could exclude all known SCAs by
direct testing or by linkage analysis. By com-
bining linkage data and whole exome sequenc-
ing (WES), we identified a mutation in the
MME gene as the causative of the disease.
Of interest, recessive MME mutations have
been recently found in participants with a very
similar peripheral neuropathy but without cer-
ebellar involvement.3
METHODS We collected DNA samples of 28 family mem-
bers, including 7 living affected individuals. We reviewed the
clinical records of the 7 living affected individuals. Experienced
neurologists at university hospitals in Brussels or Liège had col-
lected personal and family history and performed general clinical
and neurologic examinations. Results of EMG and nerve conduc-
tion studies were available for all 7 patients. Brain MRI was
performed in 2 participants, and a sural nerve biopsy was ob-
tained from 1 individual.
Linkage analysis. We performed linkage analyses on DNA
from the 7 affected and 14 unaffected family members. First,
we performed a whole genome scan with a set of 400 highly poly-
morphic microsatellite markers spaced at an average distance of 8.7
cM throughout the human genome (Marshfield set 10). Next, link-
age was retested by using an array of single nucleotide polymor-
phisms (SNPs). The programs LINKAGE and GENEHUNTER
were used for linkage analysis.
Whole exome sequencing. DNA was extracted from the lym-
phocytes according to standard procedures. WES was first per-
formed on an affected individual (III-4 figure 1) at the Beijing
Genomics Institute (BGI). Exonic sequences were enriched by
hybridization on an Agilent SureSelect All Exon v1 capture kit,
amplified, and 90 bp paired-end sequenced using an Illumina
HiSeq2000 sequencer (Illumina, San Diego, CA). WES was then
performed on another affected individual (IV-19, figure 1) at
AROS Applied Biotechnology A/S (Aarhus, Denmark), where
enrichment was accomplished by using Illumina TruSeq Exome
Enrichment Kit, followed by 100 bp paired-end Illumina
HiSeq2000 sequencing. Sequence reads were filtered to eliminate
reads with more than 6 undetermined nucleotides or 40 identical
bases in tandem, then aligned to the human genome GRCh36
assembly using the SOAPaligner 2.20 software, and the
genotypes were called using the SOAPsnp program.4 We used
the Burrows–Wheeler Alignment Tool and the Genome Analysis
Toolkit to detect insertions and deletions (indels). Single nucleotide
variants and indels were annotated using the Ensembl V54
database. We then filtered variants for being heterozygous, shared
by the 2 sequenced individuals, unique in our local exome
database, predicted to be of moderate or high effect by the
SnpEff toolbox (http://snpeff.sourceforge.net), and mapping to
nonexcluded genomic regions, i.e., with Lod scores .22 by
multipoint linkage analysis.
Follow-up DNA analysis. To confirm the candidate mutation
by Sanger sequencing, we designed oligonucleotide primers to amplify
a 250 bp fragment of the MME gene where the identified variant is
located (forward primer: 59-TCAAGAACCCAAAACTGAAGA-39,
reverse primer: 59-TTGCTACTGGCCACCCATA-39). The ampli-
fied fragments were sequenced using the Big Dye Terminator Cycle
Sequencing Kit v2 (Applied Biosystems, Foster City, CA) and ana-
lyzed on a 3130 Genetic Analyzer sequencing machine (Applied
Biosystems). All available family members (24/28), 7 of whom
affected, were tested for the candidate mutation to confirm cosegre-
gation with the disease. The mutation was also searched by Sanger
sequencing in 96 unrelated individuals with an SCA of unidentified
genetic cause.
Standard protocol approvals, registrations, and patient
consents. The Ethics Committee of the Hôpital Erasme, Brussels,
Belgium, approved this study. All family members provided written
informed consent for genetic analysis.
RESULTS Clinical description. The proband, a woman
aged 69 years at the time of examination, presented
with gait and balance problems and pain in the distal
lower limbs from around age 58. Clinical neurologic
examination showed bilateral pes cavus, mild distal
lower limb atrophy, bilaterally weak knee tendon re-
flexes and absent Achilles tendon reflexes, ataxic gait
with difficulties in turning, mild upper and lower limb
ataxia, mild upper limb cogwheel rigidity, bilaterally
positive palmomental reflex, hypometric saccades,
and mild dysarthria. Sensory examination was normal,
and there was no orthostatic hypotension. Her medical
history included hypercholesterolemia and appendec-
tomy. She did not smoke, and there was no history
of excessive alcohol consumption. EMG performed
at ages 69 and 70 demonstrated progressive, severe
motor neuropathy in the lower limbs with significantly
increased F-response latency but preserved sensory re-
sponses. Nerve conduction velocities were normal.
Lumbar CT and MRI, as well as lumbar puncture,
were normal. Serum antiganglioside and anti-MAG
antibodies were negative. Brain MRI showed moderate
cerebellar vermis atrophy (figure 2).
Seven other family members, of whom 1 was
deceased when the molecular genetic study was
started, presented with late-onset (42–68 years old)
balance problems. Clinical examination performed in
the remaining 6 patients when they were 47–72 years
old showed signs of polyneuropathy, associated with
a cerebellar syndrome in 5 (table). None of them
reported cognitive problems, but formal cognitive
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assessment was not performed. Two participants
had an MRI showing cerebellar vermis atrophy.
One individual (III-14) underwent sural nerve
biopsy, revealing axonal pathology consistent with
a Charcot–Marie–Tooth type 2 (CMT2) polyneur-
opathy. The pedigree was consistent with autosomal
dominant inheritance (figure 1).
Genetic analyses. SCA1, 2, 3, 6, and 7 were excluded
from the routine diagnostic testing in the proband
(III-4, figure 1). The first genome scan allowed us to
exclude all the known SCA loci at the time it was
performed (2004), as well as most of the genome, with
4 remaining unexcluded regions on chromosomes 3p,
3q, 7p, 8q, and 22p. A subsequent analysis with an
SNP array allowed us to exclude the 7p region and to
refine the other candidate linked regions. The highest
LOD score (Z 5 2.47) was obtained on chromosome
3q23-q26.31, defining a 31.3 Mb candidate region
between the markers D3S3694 and rs1488547.
Four variants identified by WES fulfilled our fil-
tering criteria. They affected the MME and GOLIM
genes on chromosome 3q, the FER1L6 gene on chro-
mosome 8q, and the PPIL2 gene on chromosome 22p.
Variants in the GOLIM, FER1L6, and PPIL2 genes
were listed in the SNP database (dbSNP, http://www.
ncbi.nlm.nih.gov/SNP/index.html) and/or in the
exome variant server (EVS, http://evs.gs.washington.
edu/EVS/), making them very unlikely candidates for
a rare dominant disease with a clear neurologic pheno-
type. The shared heterozygous variant in the MME
gene, a G.A transition on chromosome 3q25.2 at
position 156317031, was not present in dbSNP and
EVS. It was also absent from the exAC database
(http://exac.broadinstitute.org/), spanning 60,706
unrelated individuals sequenced as part of various
disease-specific and population genetic studies. It re-
sults in a Cys.Tyr substitution (p.C143Y) predicted
to be damaging by SIFT (score 0, median information
2.66), PolyPhen-2 (score 1.000), and PROVEAN
(score 210.185). Furthermore, the mutated residue
is in a highly conserved region and is invariant in all
species carrying a homolog of the MME gene. Segre-
gation of the mutation with the phenotype was con-
firmed by Sanger sequencing in the 2 participants who
had WES and in 22 additional family members,
Figure 2 Brain MRI scan of the proband
Sagittal T2-weighted MRI image from individual III-4 show-
ing moderate atrophy of the cerebellar vermis.
Figure 1 Family pedigree
Extended pedigree of the Belgian spinocerebellar ataxia family. The proband, individual III-4, is indicatedwith an arrowhead.MME genotypes are indicated as
WT (C143) or M (Y143).
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including all affected individuals (figure 2). Sequencing
in 96 individuals presented with dominant ataxia of
unknown cause did not identify any other carrier of
this mutation.
DISCUSSION Affected individuals in this family
developed a late-onset, motor-predominant axonal
polyneuropathy associated with cerebellar signs in all
cases but one, presenting with ataxia with mixed
afferent and cerebellar features. Pectus carinatum,
although not omnipresent, seems to be a distinctive
clinical feature. Genetic analyses, including WES
performed in 2 affected individuals, identified
a variant in the MME gene, p.C143Y, fulfilling
several criteria for pathogenicity, including absence in
control databases, cosegregation with the phenotype,
and predicted damaging effect on the encoded
protein.5 Although we could not find a second SCA
family with the same mutation among the 96 we
screened, the recent identification of recessive MME
mutations in 10 unrelated individuals from Japan with
an essentially identical polyneuropathy, but no cerebral
or cerebellar atrophy, supports the causality of the
MME mutation in our study family, despite the
dominant mode of transmission and the presence of
cerebellar involvement.3 In this regard, it is well
recognized that mutations in the same gene may lead
to different phenotypes and modes of transmission, and
such observations are becoming common as next-
generation sequencing allows solving a much larger
number of cases of genetic disorders, including ataxias.6
Experimental functional studies on the p.C143Y MME
variant are needed to understand the reason for its
dominant effect. While all prediction algorithms we
used (SIFT, PolyPhen-2, and PROVEAN) indicated
a strong deleterious impact of the p.C143Y variant, the
identification of recessive mutations, some leading to
complete loss of the MME expression,3 makes
haploinsufficiency an unlikely mechanism.
MME encodes neprilysin (NEP), a zinc-dependent
metalloprotease that cleaves peptides at the amino side
of the hydrophobic residues. NEP is expressed in most
tissues, including the central and peripheral nervous
systems (CNS and PNS). In the CNS, the expression
is almost exclusively neuronal, particularly in axons and
synaptic terminals,7 while in the PNS, the expression is
mostly in Schwann cells,8 but NEP has also been
shown to be transported along sciatic nerve axons.9
Together with the endothelin-converting enzymes
(ECE-1 and ECE-2), the erythrocyte surface antigen
KELL, and the PEX gene product, NEP belongs to
the M13 subfamily of mammalian neutral endopep-
tidases.10 These are cell membrane proteins com-
posed of a short N-terminal cytoplasmic domain,
followed by a single transmembrane helix, and a large
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alpha-helical (peptidase M13) domains connected by
a linker region. There are 12 cysteine residues in the
NEP extracellular portion, all involved in disulfide
bridges, 10 of which are also conserved in ECE,
KELL, and PEX. Cysteine 143, mutated in our study
family, is one of these 10 cysteines. It is localized in the
N-terminal peptidase M13 domain and forms a disul-
fide bridge with cysteine 411 in the linker portion10
(figure 3).
NEP acts on many substrates, including neurope-
tides such as glucagon, enkephalins, cholecystokinin,
neuropeptide Y, substance P, somatostatin, neuroten-
sin, oxytocin, prodynorphin and bradykinin, as well
as the amyloid beta (Ab) peptides accumulated in
Alzheimer disease (AD). Because of its activity on
Ab and its higher expression in entorhinal, hippo-
campal, and cortical areas, NEP has been intensively
scrutinized for a possible pathogenic role and as
a potential therapeutic target in AD.11 However,
although Mme knockout mice and mice exposed to
NEP inhibitors have increased brain Ab levels,12 they
do not develop AD-like pathology. While some stud-
ies reported amyloid deposition and neurodegenera-
tive changes in their hippocampus,13 a more recent
study surprisingly found cognitive improvement in
these animals as they age and no amyloid plaques in
their brains.14 No MME mutations are known to
cause familial AD, while genetic association studies
have provided only limited evidence of association
betweenMME polymorphisms and risk of AD.15 Fur-
thermore, none of the Japanese CMT2 patients with
MME mutations were found to be cognitively
impaired after detailed neuropsychological testing,
and amyloid PET imaging was negative in the single
case in which it was performed.3 Cognitive impair-
ment was also not a feature in our study family.
Taken together, these findings indicate that although
NEP expression has been reported to decrease with
age and in AD, NEP deficiency does not lead to the
development of AD, possibly because other enzyme
systems degrade excess Ab and prevent amyloid pla-
que formation.
The pathogenesis of peripheral neuropathy due to
MME mutations is still unclear. It has been hypoth-
esized that NEP has a role in axon–Schwann cell
interaction,3 but experimental studies are needed to
explore its physiologic role and the consequences of
its impaired or loss of function. Equally unknown is
the role of NEP in the cerebellum and the reason why
recessive loss-of-function mutations do not affect this
structure, while the p.C143Y mutation causes cere-
bellar dysfunction and atrophy. A possible lead comes
from the fact that prodynorphin, the precursor of the
opioid neuropetides a-neoendorphin and dynorphins
A and B (Dyn A and B), is an NEP substrate, and
mutations affecting the prodynorphin (PDYN) gene
cause SCA23.16 Of interest, some SCA23 mutations
alter the equilibrium between Dyn A and B and raise
dynorphin peptide levels, which could be mimicked
by altered NEP function.17 The p.C143Y mutation
may have some specific effect on NEP activity on
dynorphin peptides, possibly competing with wild-
type NEP for substrate affinity and catalytic activity,
which eventually triggers cerebellar degeneration.
Conversely, as dynorphin is a potent NEP inhibitor,18
impaired NEP activity might be implicated in SCA23
pathogenesis. Clearly, further research is needed to
address these questions. ExistingMme knockout mice
should in principle model human recessive polyneur-
opathy cases, but interestingly they do not develop
a severe axonal neuropathy, suggesting important
interspecific differences. For this reason, there is a high
risk that a mouse model carrying the p.C143Y muta-
tion, obtained by classical knock-in approaches or by
genome editing, would also not recapitulate the
human phenotype associated with this mutation.
By combining linkage analysis and WES, we
found a variant in the MME gene, p.C143Y, that
responds to several criteria for pathogenicity, i.e., rar-
ity, cosegregation with the phenotype, predicted del-
eterious effect, absence of other identified potential
pathogenic variants by exome sequencing, and
involvement of a gene proven to be mutated in fam-
ilies with a closely related phenotype. While func-
tional studies will be needed to study pathogenic
mechanisms, we consider that current evidence suffi-
ces to propose this mutation as disease causing in our
study family, identifying a novel SCA genotype
(SCA43) as well as a novel phenotype associated with
a specific MME mutation.
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